Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Single-arm, Open-label Phase II Clinical Study of Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer

NCT05841134 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Zhengzhou University as lead sponsor.

NCT NCT05841134
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05841134 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Single-arm, Open-label Phase II Clinical Study of Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer
Lead sponsor
The First Affiliated Hospital of Zhengzhou University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 1, 2023
Completion date
January 31, 2027
Enrollment
25 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

capecitabine, msi-h colorectal cancer, oxaliplatin, tislelizumab